EDAP rises on US trial news:
This article was originally published in Clinica
EDAP TMS saw its share price rise last week, after announcing that it is fast-tracking the ongoing US trial of its high intensity focused ultrasound (HIFU) treatment for prostate cancer. Its Ablatherm integrated imaging device is designed to target and deliver HIFU energy to the prostate, resulting in thermal destruction of prostate tissue. It is intended for the primary treatment of patients with low risk, localised prostate cancer. The US trial began in April 2006 and is designed to enrol 446 patients. Ablatherm is already approved for sale in the EU, South Korea, Canada and Russia, according to the Vaulx-en-Velin, France-based firm.